Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 10Neoplasms 9Leukemia, Myeloid, Acute 9Glioblastoma 9Colorectal Neoplasms 8Neoplasm Metastasis 7Prostatic Neoplasms 6Pancreatic Neoplasms 6Lung Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Carcinoma, Hepatocellular 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Myelodysplastic Syndromes 5Multiple Myeloma 5Hematologic Neoplasms 5Ovarian Neoplasms 4Glioma 4Carcinoma, Renal Cell 4Uterine Cervical Neoplasms 3Sarcoma 3Melanoma 3Head and Neck Neoplasms 3Triple Negative Breast Neoplasms 2Solid Tumors 2Solid Tumor 2Recurrence 2Rectal Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Osteosarcoma 2Neoplasm, Residual 2

Interventions

trifluridine tipiracil drug combination 1Nivolumab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Microsatellite-stable Colorectal Cancer × 90 days × Clear all
NCT07011550 2026-03-20

Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer

M.D. Anderson Cancer Center

Phase 2 Suspended
7 enrolled
Gastrointestinal

Microsatellite-stable Colorectal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡